

# Index

## A

Abnormalities, patterns of, 2, 3  
Alagille Syndrome Alliance (ALGSA), 8–9  
American College of Medical Genetics and Genomics (ACMG), 39  
Amniotic epithelial cells, 171, 175  
Amniotic fluid stem cells (AFSCs), 169, 170, 176  
Aneurysm, 77  
Antihistamines, 58  
Aortic conduit reconstruction (ACR), 100  
Aortic valve stenosis, 79  
Arterial anastomosis, 100  
Arteriohepatic dysplasia, 77  
Attention deficit hyperactivity disorder (ADHD), 160

## B

Bile acid resins, 59  
Bile duct development. *See also* Intrahepatic bile duct (IHBD) system, 8, 177  
Bile duct paucity, 1, 2, 4, 22, 49, 51, 52  
Biliary atresia (BA), 69–74, 114  
Biliary system, 11, 12  
Biliary tree stem cells (BTSCs), 175  
Bioengineering new organ, 176–177  
Bioinformatics, 40  
Bone mineral content (BMC), 125  
Bone mineral density (BMD), 125  
Bone modeling, 130  
Bone remodeling, 130  
Butterfly vertebrae, 123, 124

## C

Cardiovascular anomalies, 78  
CD46, 139, 148  
Cell culture models, 172  
Cell replacement therapy  
  AFSCs, 170  
  cord blood stem cells, 171  
  iPSCs, 170  
  preclinical applications, 172  
  restricted stem cells, 171  
Cerebral aneurysms, 93–96  
Child Health Questionnaire-Parent Form 50 (CHQ-PF50), 160  
*Childhood Liver Disease Research Network*, 111, 125  
Cholangiocytes, 12  
  morphogenesis, 13–14, 21  
  specification, 13, 18–23  
Cholestasis, 2, 4, 8, 50, 159  
  medications for, 58  
  surgical management, 60 (*see also* Hepatic Alagille syndrome)  
Cholestyramine, 59  
Chondrocyte, 126, 127  
Chronic kidney disease (CKD), 109  
CK19-positive cholangiocytes, 14  
Clinical testing, 37–39  
Coarctation of the aorta (CoA), 77, 79, 93  
Common variable immunodeficiency (CVID), 139  
Complement system, 138  
Congenital anomalies of the renal and urinary tract (CAKUT), 104

- Congenital cardiovascular disease  
 clinical outcomes, 87–88  
 diagnosis, 85–86  
 frequency, 77  
 surgical management, 86–87
- Congenital heart disease, 77, 78, 80, 85, 86
- Cord blood stem cells, 169, 171
- Craniofacial development, 128
- CRISPR/Cas9 technology, 182
- Cystic fibrosis transmembrane conductance regulator (CFTR), 180
- D**
- Dyslipidemia, 83
- E**
- Endochondral ossification, 126
- Endogenous reparative mechanisms, 183, 184
- End-stage liver disease, 85
- End-stage renal disease (ERSD), 104
- F**
- Facial abnormalities, 122
- Fractures, 121
- G**
- Genotype-phenotype correlations, 41–42
- Glomerular mesangiolipidosis, 111
- Growth failure, 55, 162
- H**
- Hajdu-Cheney syndrome, 37
- Haploinsufficiency, 8, 35, 145
- HCC, *see* Hepatocellular carcinoma
- Health related quality of life (HRQOL)  
 ADHD, 160  
 cardiac disease, 162  
 neurocognitive outcomes, 163–164  
 posttransplant outcomes, 162–164  
 pruritus, 161  
 sleep problems, 162  
 xanthomas, 162
- Hepatic Alagille syndrome  
 biochemical profile, 51  
 clinical features, 50–51  
 diagnosis, 51–52  
 histopathologic findings, 52–53  
 imaging studies, 53–54  
 management, 55  
 outcomes, 54–55
- Hepatoblasts, 13, 14, 18–20, 22
- Hepatocellular carcinoma (HCC), 62, 69
- Human Gene Mutation Database, 179
- Hypercholesterolemia, 60, 70
- I**
- IL-10, 139–141
- Immune dysregulation, 142, 144, 147, 148  
 ALGS patients  
 haploinsufficiency studies, 145–147  
 King’s College Hospital cohort studies, 142, 144  
 Jagged-Notch interactions, 147, 148  
 memory-dependent tolerance, 148  
 posttransplant complications, 148  
 consequences, 149  
 immunosuppression planning, 152  
 otorhinolaryngeal complications, 149  
 research opportunities, 152–153  
 therapeutic management, 151
- Immunology services, referral to, 150–151
- Induced pluripotent stem cells (iPSCs), 168–170, 175
- Intrahepatic bile duct (IHBD) system, 11, 18–23, 25–26  
 architecture reconstruction, 14–16  
 cholangiocyte morphogenesis, 13–14  
 cholangiocyte specification, 13  
 NOTCH intercellular signaling pathway  
 requirement, 18–20  
 threshold sensitivity, 21  
 trans-activation *vs.* cis-inhibition, 22–23  
 vascular smooth muscle defects, 25–26
- IQ scores, 163
- J**
- JAG1* mutations, 33, 35, 81
- Jag1-Notch signaling, 177
- Jagged1 mutation, 4–8, 18, 22, 25, 182–183
- Jagged1-Notch1 interactions, 138
- Jagged1-Notch-CD46 system, 139–141
- K**
- Kasai hepatoportoenterostomy, 5
- Kasai portoenterostomy, 73
- L**
- Left-sided congenital heart disease, 79
- Liver disease severity, genetic modifiers of, 42–44
- Liver transplantation (LT)

- abdominal vascular anomalies, 71–72
  - biliary diversion, 74
  - cardiac involvement, 73
  - CNS vascular events, 72
  - indication, 69
  - Kaplan-Meier analyses, 69
  - Kasai procedure, 73–74
  - living liver donation, 70–71
  - long-term outcomes, 74
  - multi-organ transplantation, 71
  - pre transplant evaluation, 73
  - published series, 68
  - vascular anomalies, 99–100
  - Liver-on-a-chip technology, 174
  - Living-related liver transplantation, 70
- M**
- Major aortopulmonary collateral arteries (MAPCAs), 84
  - Matrigel, 172, 173
  - Midaortic syndrome (MAS), 97
  - Missense mutations, 35, 37, 39–41
  - Molecular adsorbent recirculating system (MARS) dialysis, 149
  - Molecular diagnostic pipeline, 38
  - Moyamoya syndrome, 72, 93
  - mRNA therapeutics, 179
  - Multi-organ transplantation, 71
  - Musculoskeletal involvement, *see* Skeletal developmental anomalies
- N**
- Neonatal cholestasis, 4
  - Neonatal liver diseases, 4
  - Nephropathy, 149
  - Neurocognitive development, 159
  - Nonhomologous end joining (NHEJ), 183
  - Nonprotein-truncating mutations, 35
  - Nonsense read-through therapy, *see* Premature termination codon therapy
  - Notch intracellular domain (NICD), 110
  - Notch signaling pathway, 1, 5, 6, 8, 9, 16–18, 25, 92, 103, 110, 127
    - bone healing, 131
    - genome editing, 182–183
    - haploinsufficiency, 34–35
    - IHBD (*see* Intrahepatic bile duct system) vertebral development, 129
  - NOTCH2* mutations, 5, 6, 33, 34, 37
  - Notch-activating molecules, 178
  - NOTCH-independent de novo IHBD formation, 24
  - Nutritional counseling, 56
- O**
- Opioid antagonists, 59
  - Organoids, 173
  - Organ-on-a-chip technology, 172–174
  - Osteoblasts, 126, 128
  - Osteoporosis, 121
- P**
- Partial external biliary diversion (PEBD) surgery, 60, 70
  - Patient-specific drug testing, 174
  - Pediatric liver transplantation, 67, 68, 74
  - PedsQL™ generic core scale, 160, 161
  - Portal hypertension, 61
  - Premature termination codon (PTC) therapy, 179–181
  - Primitive ductal structure (PDS), 14
  - Pro-inflammatory immune dysregulation, 148
  - Protein-truncating mutations, 35, 39
  - Pruritus therapy, 7, 57–59, 143, 149, 161
  - Pulmonary artery hypoplasia, 85, 86
  - Pulmonary artery stenosis, 80, 87
- R**
- RBPJkappa (RBPJk) ablation, 183
  - Recombinant JAG1 peptides, 178
  - Regenerative nodule, 54
  - Regulators of complement activation (RCA), 139
  - Renal artery stenosis (RAS), 97
  - Renal manifestations, 110–113
    - implications, 113–114
  - Renal tubular acidosis (RTA), 111
  - Rifampin, 59
  - Right-sided congenital heart disease, 78
  - RUMI, 25–26, 43
- S**
- Selective serotonin receptor inhibitors (SSRI), 59
  - Short interspersed nuclear element upregulated (SINEUP) therapy, 182
  - Skeletal developmental anomalies
    - bone fracture, 124–126
    - butterfly vertebrae, 123–124
    - craniofacial development, 128–129
    - facial abnormalities, 122–123
    - mechanisms, 126–128
    - Notch signalling, 129–131
  - Somatic cells, 170

Studies in Pediatric Liver Transplantation  
(SPLIT) database, 69–71, 100, 113,  
164

Surgical arterioplasty, 87

Surgical biliary diversions, 61

Systemic vascular anomalies, 96–99

## T

Tetralogy of Fallot, 77, 79, 80, 82–84, 87

Th1 lymphocyte, 143

Th1 vs Th2 lymphocytes, 138, 140, 143, 144,  
147

3D culture systems, 173

Transdifferentiation, 183–184

Tubulogenesis, 12

Two-dimensional echocardiography, 85

## U

UNOS database of US pediatric liver  
transplant, 114

Ursodeoxycholic acid, 58, 161

US organ transplant registry, 68

## V

Valvular endothelial cells (VECs), 176

Valvular interstitial cells (VICs), 176

Variable expressivity, 41

Vascular anomalies

    cerebral aneurysms, 93

    LT, 99–100

    systemic bleeding episodes, 99

Vertebral abnormalities, 123

Vitamin A deficiency, 57

Vitamin D deficiency, 56

Vitamin E deficiency, 57

Vitamin K supplementation, 57

## X

Xanthomata, 51